tirzepatide new england journal of medicine Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function Tirzepatide causes more weight loss
Pay in 4 interest-free payments of $7.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

















![Iron Hands ex - Paradox Rift (Special Illustration Rare) [PAR-248] Edition:Normal](https://cdn.shopify.com/s/files/1/0549/9738/5297/files/740791.jpg?v=1774572374)



